Last reviewed: May 14, 2026
Last updated: May 14, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
GLP-1 medication shortages have persisted due to overwhelming demand, manufacturing capacity limits, and supply chain disruptions affecting both brand-name and generic formulations. Recent FDA data shows persistent backorders across multiple GLP-1 manufacturers, creating gaps in patient access and treatment continuity.
For patients navigating these access challenges, understanding alternative sourcing pathways and what genetic predispositions mean for treatment response may help support more informed conversations with healthcare providers about maintaining therapeutic continuity.
Manufacturing Constraints and Market Demand Driving Supply Gaps
GLP-1 demand has exceeded manufacturing capacity since 2023, driven by increased prescribing for both diabetes and weight management. Multiple pharmaceutical manufacturers report extended production timelines and raw material sourcing constraints, creating cascading delays across wholesale and retail channels.
Supply prioritization has favored higher-dose formulations and specific brand products, leaving gaps in lower-dose options and generic alternatives. These bottlenecks directly impact patient access, forcing treatment delays, dose adjustments, or medication switches mid-course.
Compounded Pharmacy Sourcing: Navigating Regulatory Pathways and Quality Standards
Licensed 503A compounding pharmacies operate under state pharmacy boards and FDA oversight, creating formulations when commercial supply is constrained. These pharmacies compound semaglutide, tirzepatide, and other GLP-1 medications from pharmaceutical-grade ingredients, offering continuity when branded products are unavailable.
| Sourcing Pathway |
Regulatory Framework |
Quality Assurance |
Typical Timeline |
| Brand-Name GLP-1 |
FDA-approved NDA |
Manufacturing-level GMP |
Backorder-dependent |
| Generic GLP-1 |
FDA-approved ANDA |
Manufacturing-level GMP |
Often unavailable |
| 503A Compounded |
State pharmacy board + FDA oversight |
Pharmacist-verified formulation |
Days to weeks |
| 503B Outsourcing |
Federal facility registration |
Variable quality standards |
Not recommended for GLP-1 |
Understanding Genetic Predispositions in GLP-1 Peptide Pathways
Genetic variants in GLP-1 receptor (GLP1R), GIP receptor (GIPR), FTO, and melanocortin-4 receptor (MC4R) genes may influence how individual metabolic pathways respond to peptide-based therapies. These predispositions do not predict exact medication response but may provide context for provider conversations about treatment selection.
The Precision Peptide Genetic Test evaluates key variants—including GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313—revealing predispositions in peptide genetic pathways. When interpreted by a qualified healthcare provider, this information can support more personalized treatment discussions during access or transition scenarios.
Safety Considerations and Provider Guidance When Accessing Alternative Formulations
Transitioning between branded GLP-1 products, generics, and compounded formulations requires careful dosing oversight to prevent adverse effects or therapeutic gaps. Healthcare providers must verify ingredient consistency, strength, and formulation type (injection vs. oral) when switching sources to maintain treatment safety.
Patients should discuss compounded medication sourcing directly with their prescribing provider and verify that the compounding pharmacy operates under 503A state regulation. Pre-existing contraindications, cardiovascular history, and concurrent medications remain relevant regardless of formulation source and must guide provider decisions about treatment suitability.
How PlexusDx Supports a More Personalized Approach
PlexusDx offers compounded semaglutide, tirzepatide, and dual-peptide formulations from licensed 503A pharmacies as an alternative access pathway during supply constraints. Genetic testing through the Precision Peptide test may help provide context about predispositions in GLP-1, GIP, and weight-regulation pathways, supporting more informed provider conversations when treatment decisions need adjustment.
The Precision Peptide Genetic Test reveals predispositions in four key peptide pathway genes—GLP1R, GIPR, FTO, and MC4R. This information should be interpreted with a qualified healthcare provider and does not predict exact medication response or guarantee treatment outcomes, but can support a more personalized discussion about which formulation or compound approach may align with individual genetic context.
When access barriers or supply disruptions affect your current treatment, PlexusDx genetic insights combined with compounded pharmacy options can help bridge gaps. Sharing genetic predisposition results with your provider creates a richer clinical picture to inform decisions about continuing current therapy, adjusting dose, or exploring alternative peptide-based formulations during transitions.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Why are GLP-1 medications still in short supply?
Demand outpaced manufacturing capacity starting in 2023 due to increased prescribing for diabetes and weight management. Raw material sourcing, production timelines, and supply chain constraints continue to create backorders across multiple manufacturers and dosing levels.
What is the difference between 503A and 503B pharmacy compounding?
503A compounding pharmacies operate under state pharmacy board regulation and FDA oversight, creating medications for specific patients with documented need. 503B outsourcing facilities operate federally and produce bulk compounds; they are not appropriate for GLP-1 patient-specific compounding.
How much does compounded GLP-1 cost through PlexusDx?
PlexusDx compounded semaglutide ranges from $149 monthly; tirzepatide from $249 monthly. Oral options and specialty formulations like GLP-Squared range $249-$369/mo monthly, depending on dose and formulation.
Is switching between branded and compounded GLP-1 safe?
Yes, with provider oversight. Your healthcare provider must verify ingredient strength, formulation type (injection vs. oral), and dosing when switching sources. Compounded medications from licensed 503A pharmacies meet pharmaceutical-grade standards under state and federal regulation.
Can genetic testing predict how I will respond to GLP-1 medications?
No. The Precision Peptide Genetic Test identifies predispositions in GLP-1 pathway genes (GLP1R, GIPR, FTO, MC4R), which may provide context for provider conversations but do not predict exact medication response or guarantee outcomes. Results should always be interpreted with your healthcare provider.
Related Reading
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Can You Lose Weight with GLP-1? Exploring the Benefits and Mechanisms of GLP-1 Medications
Can I Use Ozempic to Lose Weight? Understanding Its Role and Implications